Advertisement

Topics

Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec to Manufacture Universal Donor Cell Therapies

07:00 EDT 21 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Nohla Therapeutics, a leading developer of universal donor cell therapies for patients with hematologic malignancies and other critical diseases, and WuXi AppTec Advanced Therapies, a streamlined Contract Development and Manufac...

Other Sources for this Article

Nohla Therapeutics
Jim DeNike, 206-519-5294
Senior Director, Corporate Development & Investor Relations
jimd@nohlatherapeutics.com
or
WuXi AppTec Advanced Therapies
Jason Noga, 215-593-5464
Marketing Manager
jason.noga@wuxiapptec.com

NEXT ARTICLE

More From BioPortfolio on "Nohla Therapeutics Selects Advanced Therapies Business Unit of WuXi AppTec to Manufacture Universal Donor Cell Therapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...